529
Views
7
CrossRef citations to date
0
Altmetric
LETTER TO THE EDITOR

Effective palliation without normal tissue toxicity using low-dose ultrafractionated re-irradiation for tumor recurrence after radical or adjuvant radiotherapy

, , , &
Pages 1037-1041 | Received 04 Feb 2007, Published online: 08 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Carsten Nieder, Johannes A. Langendijk, Matthias Guckenberger & Anca L. Grosu. (2018) Second re-irradiation: a narrative review of the available clinical data. Acta Oncologica 57:3, pages 305-310.
Read now
Anne-Catherine Heuskin, Carine Michiels & Stephane Lucas. (2014) Low dose hypersensitivity following in vitro cell irradiation with charged particles: Is the mechanism the same as with X-ray radiation?. International Journal of Radiation Biology 90:1, pages 81-89.
Read now

Articles from other publishers (5)

Carsten Nieder & Michael Baumann. 2017. Re-Irradiation: New Frontiers. Re-Irradiation: New Frontiers 17 34 .
Andre Konski, Joshua E. Meyer, Michael Joiner, Michael J. Hall, Philip Philip, Anthony Shields, Erin McSpadden, Minsig Choi, Beth Adaire, Gail Duncan, Neal J. Meropol, Terrence P. Cescon & Steven J. Cohen. (2014) Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer. Radiotherapy and Oncology 113:1, pages 35-40.
Crossref
David Murray, Razmik Mirzayans & Alexander J. McEwan. 2013. Nuclear Medicine Therapy. Nuclear Medicine Therapy 383 407 .
David Murray & Michael Weinfeld. 2010. Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer. Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer 419 471 .
Carsten Nieder & Michael Baumann. 2011. Re-irradiation: New Frontiers. Re-irradiation: New Frontiers 13 26 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.